How We Work with Partners

Zephyr AI collaborates with biopharma, diagnostics, and research partners to accelerate development, optimize patient stratification, and generate real-world evidence—supporting innovation from early discovery through clinical validation and commercialization.

AIM-Bx: Predictive Biomarkers and AI-Enabled CDx

AIM-Bx is Zephyr’s AI-enabled biomarker platform that generates biologically explainable drug response predictions using real-world, clinically available data—delivered as software that layers seamlessly onto your LDT of choice.

Zephyr Nexus: Real-World Data, Ready for Action

Zephyr Nexus turns real-world data into high-confidence insights. By integrating clinical, molecular, and phenotypic data across one of the world’s largest clinicogenomic cohorts, Nexus powers:

Nexus supports partners with or without internal RWD infrastructure—enabling rapid clinical queries, robust analytic outputs, and scalable AI/ML applications.

Deep Multimodal Oncology Data Access for Discovery & Validation

Through its subsidiary Aster Insights™, Zephyr provides access to Total Cancer Care®, one of the world’s largest and longest-running observational oncology studies, conducted under the ORIEN® network.

Leading Infrastructure and Security

Zephyr AI’s Software Development Life Cycle and infrastructure engineering practices ensure that our models are benchmarked and versioned to guarantee the reproducibility and the isolation of results at all stages of our model development process.

Zephyr AI is SOC 2 Type 2 and HIPAA compliant, maintaining a SOC 2 certification for Security, Availability and Confidentiality TSCs. Click here to download Zephyr AI’s SOC 3 report. Please contact us for a copy of our full SOC 2 and HIPAA auditors report.